IN2014DN09359A - - Google Patents

Info

Publication number
IN2014DN09359A
IN2014DN09359A IN9359DEN2014A IN2014DN09359A IN 2014DN09359 A IN2014DN09359 A IN 2014DN09359A IN 9359DEN2014 A IN9359DEN2014 A IN 9359DEN2014A IN 2014DN09359 A IN2014DN09359 A IN 2014DN09359A
Authority
IN
India
Prior art keywords
opioid
methods
well
pharmaceutical composition
phosphatidylcholine
Prior art date
Application number
Other languages
English (en)
Inventor
Chun Su Yuan
Chong-Zhi Wang
Maojian Gu
dong-hai Lin
Original Assignee
Univeristy Of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univeristy Of Chicago filed Critical Univeristy Of Chicago
Publication of IN2014DN09359A publication Critical patent/IN2014DN09359A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544Phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
IN9359DEN2014 2012-05-04 2013-03-13 IN2014DN09359A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642837P 2012-05-04 2012-05-04
PCT/US2013/031078 WO2013165577A1 (en) 2012-05-04 2013-03-13 Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation

Publications (1)

Publication Number Publication Date
IN2014DN09359A true IN2014DN09359A (es) 2015-07-17

Family

ID=49514721

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9359DEN2014 IN2014DN09359A (es) 2012-05-04 2013-03-13

Country Status (13)

Country Link
US (1) US20150190523A1 (es)
EP (1) EP2854537A4 (es)
JP (1) JP2015515982A (es)
KR (1) KR20150006877A (es)
CN (1) CN104470361A (es)
AU (1) AU2013257211A1 (es)
BR (1) BR112014027496A2 (es)
CA (1) CA2872400A1 (es)
HK (1) HK1207940A1 (es)
IL (1) IL235390A0 (es)
IN (1) IN2014DN09359A (es)
MX (1) MX2014013425A (es)
WO (1) WO2013165577A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3718404A1 (en) 2014-10-17 2020-10-07 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progession

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846478B2 (en) * 2002-01-31 2010-12-07 Henkel Ag & Co. Kgaa Bioadhesive composition
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
US8911777B2 (en) * 2007-04-04 2014-12-16 Sigmoid Pharma Limited Pharmaceutical composition of tacrolimus
JP5985824B2 (ja) * 2008-07-01 2016-09-06 ザ ユニヴァーシティー オヴ シカゴ オピオイド受容体アンタゴニスト含有の粒子および使用方法
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
US20120053130A1 (en) * 2010-08-30 2012-03-01 Bristol-Myers Squibb Company Composition for enhancing absorption of a drug and method

Also Published As

Publication number Publication date
HK1207940A1 (en) 2016-02-19
CN104470361A (zh) 2015-03-25
WO2013165577A1 (en) 2013-11-07
BR112014027496A2 (pt) 2018-05-15
JP2015515982A (ja) 2015-06-04
AU2013257211A1 (en) 2014-11-27
IL235390A0 (en) 2014-12-31
CA2872400A1 (en) 2013-11-07
EP2854537A4 (en) 2016-04-06
EP2854537A1 (en) 2015-04-08
US20150190523A1 (en) 2015-07-09
MX2014013425A (es) 2015-08-14
KR20150006877A (ko) 2015-01-19

Similar Documents

Publication Publication Date Title
IL233592B (en) The compounds active as p2x4 receptor antagonists and substances containing them for the prevention and treatment of neurogenic pain
HK1210939A1 (en) Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
MX371344B (es) Antagonistas de il-4r para usarse en el tratamiento o prevención de asma persistente y asma severa.
NZ748451A (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
EP2680899A4 (en) Medicament delivery device for administration of opioid antagonists including formulations for naloxone
WO2012032209A3 (es) Uso de un agonista de trpm8 para la elaboración de un medicamento para el tratamiento de xeroftalmia, sequedad vaginal y síndrome de la boca seca y uso de un antagonista de trpm8 para la elaboración de un medicamento pra el tratamiento de la epífora.
MX354125B (es) Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.
MX366899B (es) Nuevos compuestos.
MX348933B (es) Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico.
DK201270677A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
EP2925340B8 (en) Pharmaceutical compositions comprising selective agonists of melanocortin 1 receptor and their use in therapeutic methods
HK1203391A1 (en) Administration of an antagonist of alpha 5 beta1 for anti- antiogenesis and cancer treatment 51
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
GB201210686D0 (en) V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
HK1196943A1 (zh) 作為用於治療酒精依賴和濫用的 受體拮抗劑的螺噻吩並吡喃-呱啶衍生物
IN2014DN09359A (es)
MX358211B (es) Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
TR201803744T4 (tr) Skleroderma tedavisinde kullanım için naltrekson içeren bileşimler.
MX2019009243A (es) Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa.
IN2013MU02852A (es)
PH12014501390A1 (en) Novel therapeutic use of p75 receptor antagonists
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия